In a deal that will bolster its pipeline of early stage assets in metabolic diseases, Pfizer has entered into a drug development and collaboration deal potentially worth up to US$911 M with WAVE Life Sciences to develop novel drugs on nucleic acid-based therapies to treat the underlying causes of various metabolic diseases. Initially, the deal will involve two candidates with an option of maximum up to five candidates. The lead asset will be WAVE’s apolipoprotein C-III (ApoC3) programme for metabolic disease with the remaining targets to be declared within 18 months.